Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Early Phase 1
Completed
Conditions
Carcinoma, Renal Cell
First Posted Date
2010-10-15
Last Posted Date
2020-03-26
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
20
Registration Number
NCT01221506
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase 2
Active, not recruiting
Conditions
Kidney Cancer
Interventions
Drug: Pazopanib
Drug: Bevacizumab
Drug: Everolimus
First Posted Date
2010-10-08
Last Posted Date
2024-06-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
180
Registration Number
NCT01217931
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

Phase 4
Completed
Conditions
Cancer
Interventions
Drug: pazopanib
First Posted Date
2010-09-20
Last Posted Date
2012-05-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
34
Registration Number
NCT01205230
Locations
🇺🇸

GSK Investigational Site, Greenville, South Carolina, United States

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1
Completed
Conditions
Solid Tumor
Kidney Cancer
Interventions
Drug: pazopanib
Drug: everolimus
First Posted Date
2010-08-18
Last Posted Date
2019-10-02
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
23
Registration Number
NCT01184326
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors

First Posted Date
2010-07-19
Last Posted Date
2014-11-17
Lead Sponsor
UNICANCER
Target Recruit Count
35
Registration Number
NCT01165385
Locations
🇫🇷

Centre Georges François LECLERC, Dijon, France

🇫🇷

Institut Curie, Paris, France

🇫🇷

Centre Léon Berard, Lyon, France

and more 2 locations

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

Phase 1
Completed
Conditions
Macular Degeneration
Interventions
Drug: Pazopanib
First Posted Date
2010-06-30
Last Posted Date
2017-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
15
Registration Number
NCT01154062
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Pazopanib
Drug: Sunitinib
First Posted Date
2010-06-22
Last Posted Date
2021-12-14
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
183
Registration Number
NCT01147822
Locations
🇨🇳

Novartis Investigative Site, Taoyuan County, Taiwan

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Phase 2
Completed
Conditions
Neuroendocrine Tumor
Interventions
Drug: Pazopanib
First Posted Date
2010-04-07
Last Posted Date
2015-12-29
Lead Sponsor
Samsung Medical Center
Target Recruit Count
37
Registration Number
NCT01099540
Locations
🇰🇷

Samsung Cancer Center, Seoul, Korea, Republic of

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Phase 2
Terminated
Conditions
Pancreatic Cancer
Interventions
Drug: Gemcitabine
Drug: Pazopanib
First Posted Date
2010-03-04
Last Posted Date
2015-06-09
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
2
Registration Number
NCT01080248
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

Phase 1
Completed
Conditions
Macular Degeneration
Interventions
Drug: pazopanib
Drug: Placebo
First Posted Date
2010-02-22
Last Posted Date
2017-11-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
37
Registration Number
NCT01072214
Locations
🇺🇸

GSK Investigational Site, Glendale, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy